Canada: Federal Court Adds To Uncertainty Regarding Markush Groups And Alternatives In Patent Claims

Markush groups define claimed subject matter in a form such as "the group consisting of A, B and C", whereas alternatives may be recited in a form such as "A, B or C".  In Eli Lilly Canada Inc v Mylan Pharmaceuticals ULC ("Eli Lilly v Mylan"), 2015 FC 17, the Federal Court, in upholding the patent at issue, considered the validity of claims that recite Markush groups compared to claims to alternatives.

Patent Act

The Canadian Patent Act does not explicitly address Markush groups, but does explicitly address claimed alternatives, as follows:

27. (5) For greater certainty, where a claim defines the subject-matter of an invention in the alternative, each alternative is a separate claim for the purposes of sections 2, 28.1 to 28.3 and 78.3. [emphasis added]

Sections 2, 28.1 to 28.3 and 78.3 of the Patent Act relate to substantive requirements for patentability, such as utility, novelty and non-obviousness.

Abbott decisions

In Abbott Laboratories v Canada (Minister of Health) ("Abbott I"), 2005 FC 1095, the Federal Court distinguished Markush groups from alternatives and defined a Markush claim as a claim to the entire group. In Abbott I, the Federal Court concluded that an entire Markush claim was invalid because some (but not all) of the solvents in the Markush group lacked utility.

Section 27(5) of the Patent Act could be interpreted to mean that if the solvents in the Abbott I decision had been defined as alternatives instead of as a Markush group, then each solvent would be a separate claim, and the claims to solvents that had utility could still be valid. If that interpretation of section 27(5) were correct, then alternatives might be stronger than Markush claims in Canada.

However, in Abbott Laboratories v Canada (Minister of Health)("Abbott II"), 2005 FC 1332, the Federal Court considered the same Markush claim that was at issue in Abbott I, and stated that even if the claim had recited an alternative as contemplated by section 27(5), then the whole claim would still fail if any of the alternatives were not patentable. The Court reached that conclusion by characterizing section 27(5) as "principally an administrative provision for purposes of a patent application".

The Abbott I and Abbott II decisions together seem to suggest that both Markush claims and claims to alternatives will fail entirely in Canada if they include any invalid embodiments.

Eli Lilly v Mylan

The more recent Eli Lilly v Mylan decision, on the other hand, suggests that Markush terminology may be the better choice. In that decision, the Federal Court considered claim 2 in Canadian patent no. 2,226,784, which recites the following:

  1. A pharmaceutical composition for the curative or prophylactic treatment of erectile dysfunction in a male animal, comprising a compound selected from the group consisting of:

[tadalafil] or a physiologically acceptable salt or solvate thereof; and

[3-methyl tadalafil] or a physiologically acceptable salt or solvate thereof,

together with a pharmaceutically acceptable diluent or carrier.

The issued claim includes chemical formulas, which for simplicity have been replaced by "[tadalafil]" and "[3-methyl tadalafil]" in the excerpt above.

Mylan argued that 3-methyl tadalafil lacked utility, so the Court considered whether a lack of utility of 3-methyl tadalafil would affect the validity of claim 2. Because claim 2 defines a "group consisting of" different compounds that are joined with "and", the Court characterized the claim as a Markush claim, rather than as a claim directed to alternatives that would be subject to section 27(5) of the Patent Act.

The Court reaffirmed its previous interpretation of section 27(5) in Abbott II, namely that if a claim defines alternatives, then the entire claim fails if one of the alternatives is invalid. Because claim 2 was a Markush claim, rather than a claim to alternatives, the Court concluded that section 27(5) did not apply and that claim 2 would not be invalid for lack of utility, even if 3-methyl tadalafil did lack utility. Therefore, the Court did not actually decide whether 3-methyl tadalafil lacked utility. The Court's approach in Eli Lilly v Mylan appears to be contrary to Abbott I, in which the Federal Court rejected a Markush claim that included both valid and invalid embodiments.

The Eli Lilly v Mylan decision has been appealed to the Federal Court of Appeal, which may clarify the significance of claims to Markush groups and the impact of section 27(5).

Claim drafting considerations

In some cases, Markush groups are important forms for defining claimed genera. In other cases, and particularly in jurisdictions where excess claims fees are charged, patent applicants may define Markush groups or alternatives to try to reduce or avoid excess claims fees. However, Canadian patent applications do not incur excess claims fees, so where practical, reciting separate elements in separate claims may be prudent to avoid the ongoing uncertainty regarding Markush groups and alternatives.

For further information, please contact a member of our firm's Patents group.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions